Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Circulating Tumor Cells Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?#_x000D_
The circulating tumor cells market has expanded significantly in recent years. It is projected to increase from $13.27 billion in 2025 to $14.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. This historical expansion can be primarily attributed to several factors including increasing cancer incidence rates, the broadening of oncology research programs, the growing utilization of blood-based diagnostics, the rising uptake of minimally invasive testing methods, and the accessibility of advanced laboratory technologies._x000D_
_x000D_
The circulating tumor cells market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $23.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.3%. This anticipated growth during the forecast timeframe stems from factors such as the heightened uptake of personalized oncology diagnostics, increased funding in cancer biomarker investigations, the spread of automated cell capture solutions, the escalating need for early-stage cancer detection instruments, and the greater incorporation of AI into oncology diagnostics. Key developments expected throughout the forecast period encompass a wider utilization of liquid biopsy methods, a growing embrace of microfluidic CTC isolation devices, increased integration of automated CTC analysis platforms, an broadening of oncology research uses, and a sharpened emphasis on detecting cancer early._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Circulating Tumor Cells Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
The anticipated rise in cancer cases is projected to significantly propel the expansion of the circulating tumor cells market going forward. Cancer is defined as a disease where some body cells grow uncontrollably and disseminate to other parts. Circulating tumor cells are utilized to assist in the early detection and diagnosis of cancer, and thus the escalating incidence of cancer fuels the growth of the circulating tumor cells market. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, more than 35 million new cancer cases are anticipated in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Consequently, the increasing incidence of cancer is driving the growth of the circulating tumor cells market._x000D_
_x000D_
#Circulating Tumor Cells Market Segments: Where Is Growth Concentrated?#_x000D_
The circulating tumor cells market covered in this report is segmented – _x000D_
_x000D_
1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems_x000D_
2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis_x000D_
3) By Application: Clinical Or Liquid Biopsy, Research_x000D_
_x000D_
Subsegments:_x000D_
1) By Kits And Reagents: Cell Enrichment Kits, Detection Kits, Nucleic Acid Isolation Kits _x000D_
2) By Blood Collection Tubes: Standard Blood Collection Tubes, Specialized Blood Collection Tubes _x000D_
3) By Devices Or Systems: Microfluidic Devices, Automated Cell Capture Systems, Imaging Systems _x000D_
_x000D_
#Circulating Tumor Cells Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Companies operating in the circulating tumor cells (CTC) market are prioritizing the creation of innovative solutions, such as biomarker-specific CTC assays, to satisfy the increasing need for accurate, non-invasive cancer detection and sophisticated personalized therapy monitoring. Biomarker-specific CTC assays allow for the identification and detailed characterization of circulating tumor cells based on particular protein expressions, providing more comprehensive phenotypic data than conventional CTC enumeration methods, which primarily deliver total cell counts without specific biomarker differentiation. For example, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics company, introduced the CELLSEARCH CTC test with the DLL3 biomarker, which is now available as a Research Use Only (RUO) service in North America and Europe. This assay leverages the FDA-cleared CELLSEARCH platform to detect circulating tumor cells that express DLL3, a protein found in high levels in aggressive small-cell lung cancer (SCLC) and neuroendocrine tumors. By targeting DLL3, the test facilitates the phenotypic characterization of CTCs linked to poor prognoses, thereby supporting biopharma research in developing specific targeted therapies. This innovation offers researchers a non-invasive tool to investigate tumor diversity, track disease progression, and assess reactions to targeted treatments._x000D_
_x000D_
#Circulating Tumor Cells Market Key Players Shaping Industry Direction#_x000D_
Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc. _x000D_
_x000D_
#View The Full Circulating Tumor Cells Market Report:#_x000D_
_x000D_
#Circulating Tumor Cells Market Regional Analysis: Which Geography Leads On Revenue?#_x000D_
North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.